Cardiac electrophysiologic and antiarrhythmic actions of 3,4-dihydro-1'- [2-(benzofurazan-5-yl) ethyl]-6-methanesulfonamidospiro [(2H)-1- benzopyran-2,4'-piperidin]-4-one HCl (L-691,121), a novel class III agent

JJ Lynch , AA Wallace, LH Van der Gaag, EP Baskin, CM Bear, JR Gehret, T Kothstein, RF Stupienski, SD Appleby and MC Sanguinetti

Department of Pharmacology, Merck Research Laboratories, West Point, Pennsylvania.

The cardiac electrophysiologic and antiarrhythmic actions of 3,4- dihydro-1'-[2-(benzofurazan-5-yl)ethyl]-6-methyl-sulfonamid ospiro [(2H)-1-benzopyran-2,4'-piperidin]-4-one HCl (L-691,121), a novel spirobenzopyran piperidine class III agent, were assessed in vitro and in vivo. In ferret isolated papillary muscles, L-691,121 significantly prolonged effective refractory period (EC25 = 13 nM) and elicited a modest positive inotropic effect. In guinea pig isolated ventricular myocytes, L-691,121 prolonged action potential duration by selectively blocking (IC50 = 4.4 nM) a rapidly activating and rectifying component of the delayed rectifier K+ current, Ikr. The class III activity of L- 691,121 in isolated papillary muscles was reverse frequency-dependent, and reversed by hypoxic perfusion. L-691,121 modestly depressed spontaneous beating rate (-14%) in guinea pig isolated right atria at concentrations up to 3 microM. In anesthetized dogs, the i.v. administration of 10 to 100 micrograms/kg of L-691,121 significantly increased atrial and ventricular refractoriness and prolonged the electrocardiographic Q-T interval, but did not alter atrioventricular nodal, His-Purkinje, atrial or ventricular conduction. In conscious dogs with spontaneous premature ventricular complexes at 48 hr after myocardial infarction, 10 to 1000 micrograms/kg i.v. of L-691, 121 failed to reduce premature ventricular complex frequency. However, in anesthetized dogs studied chronically (7.9 +/- 0.3 days) after infarction, 10 and 100 micrograms/kg i.v. of L-691,121 suppressed the induction of ventricular tachyarrhythmia by programmed stimulation in 8/14 (57%) and 11/14 (79%) dogs tested, respectively, and reduced the incidence of lethal ventricular arrhythmias triggered by a secondary myocardial ischemic event from 14/15 (93%) in vehicle controls to 5/14 (36%; P < .01) in L-691,121-treated (100 micrograms/kg i.v.) animals. The latter findings suggest the potential for L-691,121 to prevent the development of malignant ventricular arrhythmias in the setting of previous myocardial infarction.

Volume 265, Issue 2, pp. 720-730, 05/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				M. Zaniboni, A. E. Pollard, L. Yang, and K. W. Spitzer Beat-to-beat repolarization variability in ventricular myocytes and its suppression by electrical coupling Am J Physiol Heart Circ Physiol, March 1, 2000; 278(3): H677 - H687. [Abstract] [Full Text] [PDF]

				S. Vickers, C. A. Duncan, D. E. Slaughter, B. H. Arison, T. Greber, T. V. Olah, and K. P. Vyas Metabolism of MK-499, a Class III Antiarrhythmic Agent, in Rats and Dogs Drug Metab. Dispos., May 1, 1998; 26(5): 388 - 395. [Abstract] [Full Text]

				T. Yang, D. J. Snyders, and D. M. Roden Ibutilide, a Methanesulfonanilide Antiarrhythmic, Is a Potent Blocker of the Rapidly Activating Delayed Rectifier K+ Current (IKr) in AT-1 Cells : Concentration-, Time-, Voltage-, and Use-Dependent Effects Circulation, March 15, 1995; 91(6): 1799 - 1806. [Abstract] [Full Text]